Navigation Links
Helsinn Announces the Acquisition of Sapphire Therapeutics Inc., USA to Establish Helsinn Therapeutics (US) Inc.
Date:1/28/2009

fects (appetite, gain weight, quality of life) and a good safety and tolerability profile (end Phase II);

- ipamorelin, for the i.v. treatment of post operative ileus, the impairment of bowel motility following surgery, an unmet medical need (Phase II);

- ST-1141, a new oral compound, for the treatment of opioid-induced bowel dysfunction (Phase I);

- Other products at research stage.

The acquisition will have a direct, positive impact on the Helsinn Group since the production of Helsinn Therapeutics (US) Inc. products will be manufactured in Helsinn's high standard quality manufacturing facilities in Switzerland which operate according to EU and FDA health and environmental requirements.

About Helsinn Group

Helsinn is a privately owned pharmaceutical group with headquarters in Lugano, Switzerland. Helsinn's unique business model is focused on the licensing of pharmaceuticals and medical devices in therapeutic niche areas. The Group in-licenses early stage new chemical entities, completes their development from the performance of pre-clinical/clinical studies and Chemistry, Manufacturing and Control (CMC) development, to the filing for and attainment of their market approval worldwide.

Helsinn's products are sold directly, through the Group subsidiaries, or eventually out-licensed to its network of local marketing and commercial partners, selected for their deep in-market knowledge and know-how, and assisted and supported with a full range of product and scientific management services, including commercial, regulatory, financial, legal and medical marketing advice.

The active pharmaceutical ingredients and the finished dosage forms are manufactured at Helsinn's cGMP facilities in Switzerland and Ireland, and supplied worldwide to its customers.

Helsinn is the worldwide licensor of palonosetron, a second generation 5-HT3 r
'/>"/>

SOURCE Helsinn Healthcare SA
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Helsinn Healthcare and Zealand Pharma Sign a Partnering Agreement for ZP1846, a Novel GLP-2 Agonist
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
4. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
5. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
6. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
7. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
8. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
9. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
10. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
11. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... 1, 2015   Decision Resources Group ... of Otezla are its oral administration, alternative mechanism ... by surveyed rheumatologists. Otezla was the first oral ... of active psoriatic arthritis in the ... care includes conventional oral treatments including disease-modifying antirheumatic ...
(Date:7/1/2015)... and BANGALORE, India , ... genomic profiling company that uses next generation sequencing technology ... Scott A. Storrer as chief executive officer. ... he will be responsible for all strategy, business expansion ... , who has served as Strand,s chairman and CEO ...
(Date:7/1/2015)... , July 1, 2015  Axovant Sciences ... focused on the treatment of dementia, today announced ... on July 22 at 5:45 p.m. EDT following ... Alzheimer,s Association International Conference 2015 (AAIC). ... , Dr. Lawrence Friedhoff , ...
(Date:7/1/2015)... ... 2015 , ... A newly launched business plan contest will ask startup companies ... in life sciences R&D. The Pistoia Alliance President’s Startup Challenge 2015 will see small ... period of expert mentorship from a senior industry figure drawn from the Pistoia Alliance ...
Breaking Biology Technology:Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 2Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 3Strand Life Sciences Names Scott A. Storrer CEO as Company Continues Global Expansion with Focus on Precision Medicine Product 2Strand Life Sciences Names Scott A. Storrer CEO as Company Continues Global Expansion with Focus on Precision Medicine Product 3Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 2Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 3Pistoia Alliance Launches Startup Challenge 2Pistoia Alliance Launches Startup Challenge 3
... Feb. 1 Fears that the economy is not,only ... had,investors in a skittish mood during January. However, biotech ... well ahead of the,NASDAQ, which posted a January loss ... "Healthcare is usually able to ride out extremely volatile ...
... 1 Taligen Therapeutics, Inc. today,announced it anticipates ... Series B,financing. The financing was led by Alta ... including Sanderling Ventures, Tango,and High Country Venture., ... infusion of capital but the,addition of two world ...
... DIEGO, Feb. 1 Cardium Therapeutics (Amex:,CXM) ... million registered direct,offering with institutional and other ... on January 31, 2008. Empire Asset Management,Company ... the transaction., (Logo: http://www.newscom.com/cgi-bin/prnh/20051018/CARDIUMLOGO ), ...
Cached Biology Technology:January Market Jitters Fails to Derail Biotech 2January Market Jitters Fails to Derail Biotech 3January Market Jitters Fails to Derail Biotech 4Taligen Therapeutics Secures Series B Financing 2Cardium Completes $5.3 Million Registered Direct Offering 2Cardium Completes $5.3 Million Registered Direct Offering 3Cardium Completes $5.3 Million Registered Direct Offering 4
(Date:6/17/2015)... Deutschland und GERMANTOWN, Maryland , June ... ®   Produktlinie mit DNA-Tests verbessert den ... (NASDAQ: QGEN ; Frankfurt Prime Standard: QIA) hat ... STR-Testkits der Produktlinie Investigator ® ... Markt eingeführt. Die neuen Kits zur Erstellung genetischer Fingerabdrücke ...
(Date:6/17/2015)... , June 17, 2015  Crossmatch™, a leading ... that its U.are.U ® 4500 fingerprint readers ... Eateries, Inc., a San Jose, ... to increase security, improve accountability and reduce fraud ... instant, non-repudiable identity confirmation for employee sign in ...
(Date:6/16/2015)... 16, 2015 Fingerprint Cards has received ... in the company,s portfolio from one of its module partners ... mainly take place during the third quarter 2015. The sensors ... . Jörgen Lantto, CEO of FPC, comments: ...   growing interest from smartphone OEMs in integrating touch fingerprint ...
Breaking Biology News(10 mins):QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 2QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 3QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 4QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 5QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 6Togo's Eateries Improve Security and Accountability with Crossmatch Fingerprint Readers 2Togo's Eateries Improve Security and Accountability with Crossmatch Fingerprint Readers 3FPC Receives Order for Touch Fingerprint Sensors of 375 MSEK 2
... in Colombia,s Cerrejn coal mine by researchers from the Smithsonian ... Natural History helps to explain the origin of one of ... Cerrejonemys wayuunaiki takes its genus name from Cerrejn, ... spoken by the Wayuu people who live on the Guajira ...
... if you are making cellulosic ethanol, you want less lignin ... are using pyrolytic methods, you want more lignin because lignin ... or minimize lignin content, an understanding of lignin synthesis is ... adaptation to life on land, as it strengthens plant cell ...
... through which it can protect itself against newly-developing cancer ... in our organs every day. Once tumours have developed, ... from the immune system. Scientists from the research group ... (HZI) in Braunschweig have now succeeded to reveal a ...
Cached Biology News:Convergent evolution in lignin biosynthesis: Tools for re-engineering biomass composition 2The immune system's guard against cancer 2The immune system's guard against cancer 3